Twist Bioscience
{{Short description|American Biotechnology company}}
{{Infobox company
| name = Twist Bioscience
| type = Public
| traded_as = {{ubl|{{NASDAQ|TWST}}|Russell 2000 component}}
| founders = {{ubl|Emily Leproust| Bill Banyai| Bill Peck}}
| industry = synthetic biology
| genre =
| products = Genes and gene fragments, NGS products
| homepage = {{URL|twistbioscience.com}}
| foundation = {{Start date and age|2013}}
| location_city = South San Francisco, California
| revenue = {{Increase}} $54.2 million(2019){{Cite web|url=https://investors.twistbioscience.com/news-releases/news-release-details/twist-bioscience-reports-fourth-quarter-and-full-year-fiscal/|title=Twist Bioscience | Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2019 Financial Results|website=investors.twistbioscience.com}}
| num_employees = 400
}}
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries.{{cite news|last1=Strickland|first1=Eliza|title=DNA Manufacturing Enters the Age of Mass Production |url=https://spectrum.ieee.org/dna-manufacturing-enters-the-age-of-mass-production|work=IEEE Spectrum: Technology, Engineering, and Science News|date=December 23, 2015|language=en}} Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.{{Cite web |last=Yassif |first=Jaime |last2=O'Prey |first2=Kevin |last3=Isaac |first3=Christopher |date=November 2021 |title=Strengthening Global Systems to Prevent and Respond to High-Consequence Biological Threats |url=https://www.nti.org/wp-content/uploads/2021/11/NTI_Paper_BIO-TTX_Final.pdf |url-status=live |archive-url=https://web.archive.org/web/20220709012345/https://www.nti.org/wp-content/uploads/2021/11/NTI_Paper_BIO-TTX_Final.pdf |archive-date=2022-07-09 |access-date=2022-07-09 |website=Nuclear Threat Initiative}}
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes.{{cite news|url=https://www.genengnews.com/news/cad-platform-developed-by-gp-write-and-twist-to-launch-large-genome-projects/|date=May 12, 2021|title=CAD Platform Developed by GP-Write and Twist to Launch Large Genome Projects|work=Genetic Engineering & Technology News}}